We're thrilled to announce that Antibodies Incorporated has joined forces with the National Cancer Institute (NCI) to offer researchers a unique opportunity to request custom monoclonal antibodies.
This partnership aims to support advancements in biomarker discovery, diagnostic development, and therapeutic monitoring through the NCI's Antibody Characterization Program.
Each antibody developed will undergo rigorous validation by the NCI's Antibody Characterization Lab and will be made accessible to the broader research community.
We're honored to have been chosen by the NCI's Antibody Characterization Program for this initiative and are dedicated to driving important progress in cancer research.
How to apply:
Submission Period: November 1, 2024 - February 14, 2025
Submit Request: Complete the online form on the NCI website.
For more information, visit:
Proteomics Program
CPTAC Antibody Portal
Let's accelerate cancer research together!
**Individuals chosen for the program are not guaranteed an antibody by Antibodies Inc.**